project id: TCGA-BLCA; case submitter id: TCGA-DK-AA6S; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.46; rna integrity number: 7.3; age at index: 60; days to birth: -22027; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 22027; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3b; ajcc staging system edition: 5th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 5050.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2000; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 4782; initial weight: 390.0; sample id: 61cf45dc-21ec-40a3-a72b-3edd21895f6b; sample submitter id: TCGA-DK-AA6S-01A; portion id: ecf99810-ad0b-4661-8b8f-29c7614db1ef; portion submitter id: TCGA-DK-AA6S-01A-21; slide id: 2d759715-02d7-436a-8fc0-3446a13e071c; slide submitter id: TCGA-DK-AA6S-01A-02-TSB; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 65.0; section location: TOP;